Clinical Priorities Advisory Group

(asked on 25th March 2019) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, which clinical policies awaiting review by the Clinical Priorities Advisory Group involve the use of the NICE commissioning support programme.


Answered by
Caroline Dinenage Portrait
Caroline Dinenage
This question was answered on 2nd April 2019

The clinical policies awaiting review by the Clinical Priorities Advisory Group, which involve the use of the National Institute for Health and Care Excellence (NICE) commissioning support work programme are as follows:

- Chenodeoxycholic acid and cholic acid for treating inborn errors in primary bile acid synthesis;

- Telotristat for treating carcinoid syndrome;

- Bictegravir-emtricitabine-tenofovir alafenamide for treating HIV-1;

- Idebenone for treating Leber hereditary optic neuropathy;

- Canakinumab for treating periodic fever syndromes;

- Emicizumab for bleed prevention in severe and moderate haemophilia A without inhibitors;

- Dolutegravir with rilpivirine for treating HIV in people with viral suppression;

- Doravirine for treating HIV infection;

- Vonicog alfa for the treatment of bleeding in adults with von Willebrand disease; and

- Mercaptamine hydrochloride for treating corneal cystine crystal deposits caused by cystinosis.

NICE’s work on Ivacaftor for treating cystic fibrosis with a R117H mutation in the CFTR gene is currently paused.

Reticulating Splines